Fig. 5From: [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center[99mTc]Tc-PSMA-I&S-SPECT/CT of an 82-year-old patient with mCRPC and disease progression under chemotherapy (docetaxel). a Pretherapeutic tumor spread (PSA 137 ng/ml). b Restaging 3 months after the second cycle of 177Lu-PSMA therapy (PSA 60 ng/ml)Back to article page